Stephen Silberstein

Prof

Thomas Jefferson University

United States

Research Interests

Explore related searches

Professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Professor Stephen Silberstein is a faculty member at Thomas Jefferson University, located in the United States. His primary research areas include the mechanisms and management of migraines, particularly focusing on therapies targeting calcitonin gene-related peptide (CGRP). His recent publications reflect advancements in headache care and clinical guidelines, contributing significantly to the understanding of migraine treatment and associated adverse events.

Articles (12)

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Collaborators (4)

Hsiangkuo Yuan

Associate Professor

UNITED STATES

View details

Christina L. Szperka

University of Pennsylvania

UNITED STATES

View details

Fred Cohen

Assistant Professor

Icahn School of Medicine at Mount Sinai

UNITED STATES

View details

Faisal Mohammad Amin

Associate Professor

University of Copenhagen

DENMARK

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Stephen Silberstein

Research Interests

Explore related searches

Contact this professor

About

Articles (12)

Insights from 25 years of onabotulinumtoxinA in migraine — mechanisms and management

Developments in targeting calcitonin gene-related peptide

A Novel Virtual-Based Comprehensive Clinical Approach to Headache Care

Adverse Events Reported with Therapies Targeting the CGRP Pathway During the First 6 Months Post-launch: A Retrospective Analysis Using the FDA Adverse Events Reporting System

Calcitonin Gene-Related Peptide (CGRP)-Targeted Monoclonal Antibodies and Antagonists in Migraine: Current Evidence and Rationale

Guidelines of the International Headache Society for Clinic-Based Headache Registries, 1st edition

Safety and tolerability of fremanezumab in patients with episodic and chronic migraine: a pooled analysis of phase 3 studies

Applicability of DSM-V substance use disorder (SUD) criteria in medication overuse headache (MOH)

Time course of efficacy of atogepant for the preventive treatment of migraine: Results from the randomized, double-blind ADVANCE trial

Intravenous ibuprofen for acute treatment of migraine: A double‐blind, randomized, placebo‐controlled pilot study

Treatment benefit among migraine patients taking fremanezumab: results from a post hoc responder analysis of two placebo-controlled trials

Guidelines of the International Headache Society for clinical trials with neuromodulation devices for the treatment of migraine

Collaborators (4)

Hsiangkuo Yuan

Christina L. Szperka

Fred Cohen

Faisal Mohammad Amin

Make your next move.